Compound agent including moxifloxacin and pidotimod

Abstract

The invention relates to a composite agent of muxixacin and pidumode, used to treat bacterial infection. The agent comprises 100-800mg muxixacin and 200-1600mg pidumode, which are both made as composite agents, that directly kills bacterial externally via the muxixacin and improve anti-infection ability via the internal anti-infection immunity ability of pidumode, with better cooperate function and wide application on general clinical bacterial infections, controlling the generations of virus infection and other abnormal pathogene infections.

Description

technical field [0001] The invention relates to a compound preparation of moxifloxacin and pidotimod for treating bacterial infectious diseases. Background technique [0002] Infectious diseases are the most common problems in clinical work, in which about 80% of infections in adults are caused by bacteria, involving outpatients and hospitalized patients. The most important means of clinical treatment of bacterial infections is the use of various antibiotics, resulting in resistance to antibiotics, and also led to problems such as complicated infections, refractory infections, and recurrent infections in the clinical treatment of such patients. At the same time, due to the increasing cycle and cost of developing new antibiotics, it is impossible to find newer and stronger antibiotics in the short term. [0003] Moxifloxacin is a product launched by Bayer AG of Germany, which belongs to the fourth-generation quinolones; chemical name: 1-cyclopropyl-7-(S,S-2,8-diazabicyclo[4....

AI Technical Summary

Problems solved by technology

[0005] Immunological studies have shown that patients with infectious diseases generally have a low level of anti-infection immunity, and relying sole

Images